Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...

The FDA has approved Novartis' Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

Exforge HCT contains the active ingredients Amlodipine Besilate, Valsartan and hydrochlorothiazide. Exforge HCT is used to control high blood pressure, also called hypertension.

Novartis AG said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in the United States of generic versions of its ...

Novartis' blood pressure drug Exforge -- a combination of the Swiss drugmaker's Diovan and the generic form of Pfizer's Norvasc -- performed better than Norvasc alone, according to a newly ...

Exforge HCT is not indicated for the initial therapy of hypertension. This approval was based on data from a clinical study in more than 2000 patients with moderate to severe hypertension.

Novartis AG agreed to pay $245 million to end antitrust litigation accusing the company of trying to delay the launch of generic versions of the drug Exforge in the United States.

The bulk of the voluntary recall, which was initiated in the summer, was for about 4.7 million bottles of hypertension treatments Exforge and a related drug, Exforge HCT, according to information ...

Exforge is expected to be available to patients in the U.S. in late September 2007, pending the expiration of market exclusivity and patent protection for amlodipine besylate.

Amlodipine (as besylate) 5 mg, valsartan 160 mg; tabs. Exforge combines two antihypertensive drugs that have complementary mechanisms of action: amlodipine, a calcium (Ca+) channel blocker, and ...

FDA approves blood pressure drug Regulators give the okay to Exforge, a blood pressure combo drug developed by Novartis and Pfizer.

Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its Exforge ...